5.62
0.12 (2.18%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | TriSalus Life Sciences, Inc. | 混合的 | - |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 5.0 |
| 平均 | 0.88 |
|
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 54.94% |
| 机构持股比例 | 13.12% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Wealthcare Advisory Partners Llc | 31 Dec 2024 | 643,740 |
| Graypoint Llc | 31 Dec 2024 | 120,355 |
| Msd Partners, L.P. | 31 Dec 2024 | 39,999 |
| Connecticut Wealth Management, Llc | 31 Dec 2024 | 22,303 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 11.00 (Roth MKM, 95.73%) | 购买 |
| 11.00 (Canaccord Genuity, 95.73%) | 购买 | |
| 中 | 11.00 (95.73%) | |
| 低 | 10.00 (Lake Street, 77.94%) | 购买 |
| 平均值 | 10.67 (89.86%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 5.44 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Canaccord Genuity | 28 Mar 2025 | 11.00 (95.73%) | 购买 | 5.62 |
| Lake Street | 13 Feb 2025 | 10.00 (77.94%) | 购买 | 5.53 |
| Roth MKM | 24 Jan 2025 | 11.00 (95.73%) | 购买 | 5.18 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合